|
|
|
|
|
by nwiswell
1630 days ago
|
|
> I think we are seeing the same thing, a system designed to remove corruption/regulatory capture/lobbying as far as possible from the process Not really. It's more like a system to selectively remove intellectual property rights without destroying the financial incentive to develop drugs. |
|
IP is an interesting point, although I'm not convinced that generating the IP is more than a small fraction of the cost of a drug. An aggregate I saw from 2011-2018 puts Research at only 17% of revenue, and only some proportion of that is geared towards generating IP. That is to say, with all else removed you could generate an IP only company for 17% the cost of drug sales.